Advertisement

Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis

      Abstract

      Objective

      Direct oral anticoagulants (DOACs) have been recommended for the treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the prevention of post-thrombotic syndrome (PTS). We performed a systematic review and meta-analysis of reported studies to assess the efficacy of DOACs vs vitamin K antagonists for the risk reduction of PTS in patients with DVT.

      Methods

      We searched PubMed, Medline, the Cochrane Library, Embase, and the Web of Science for studies reporting on the development of PTS after acute DVT. The outcomes were the risk reduction of PTS, PTS severity, the presence of residual vein thrombosis, and the incidence of recurrent venous thromboembolic (VTE) events.

      Results

      A total of 59,199 patients from six retrospective and two randomized controlled studies had received DOAC treatment and were followed up for the development of PTS. In all studies, rivaroxaban had been compared with initial low-molecular-weight heparin followed by warfarin. Of the 59,199 patients, 19,840 (33.5%) had received rivaroxaban and 39,377 (66.5%), warfarin. The rivaroxaban group had a significant reduction in PTS development compared with the warfarin group (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.43-0.63; P < .001). Severe PTS was less common in the rivaroxaban group than in the warfarin group (3.7% vs 6.4%; OR, 0.55; 95% CI, 0.36-0.85; P = .024). Additionally, rivaroxaban was associated with a significant reduction in VTE recurrence (OR, 0.83; 95% CI, 0.59-1.18; P = .03) and low rates of residual vein thrombosis compared with warfarin (36.5% vs 51.8%; P = .037).

      Conclusions

      Rivaroxaban after acute DVT was associated with a reduced risk of PTS compared with warfarin. Patients treated with rivaroxaban more rarely developed severe PTS and recurrent VTE events compared with patients treated with warfarin.

      Keywords

      To read this article in full you will need to make a payment
      SVS Member Login
      Society Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kahn S.R.
        How I treat postthrombotic syndrome.
        Blood. 2009; 114: 4624-4631
        • Prandoni P.
        • Villalta S.
        • Bagatella P.
        • Rossi L.
        • Marchiori A.
        • Piccioli A.
        • et al.
        The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients.
        Haematologica. 1997; 82: 423-428
        • Schulman S.
        • Lindmarker P.
        • Holmström M.
        • Lärfars G.
        • Carlsson A.
        • Nicol P.
        • et al.
        Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.
        J Thromb Haemost. 2006; 4: 734-742
        • Haig Y.
        • Enden T.
        • Grøtta O.
        • Kløw N.E.
        • Slagsvold C.E.
        • Ghanima W.
        • et al.
        Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5 year follow-up results of an open label, randomized controlled trial.
        Lancet Haematol. 2016; 3: 64-71
        • Galanaud J.P.
        • Kahn S.R.
        The postthrombotic syndrome: a 2012 therapeutic update.
        Curr Treat Options Cardiovasc Med. 2013; 15: 153-163
        • O’Donnell Jr., T.F.
        • Browse N.L.
        • Burnand K.G.
        • Thomas M.L.
        The socioeconomic effects of an iliofemoral venous thrombosis.
        J Surg Res. 1977; 22: 483-488
        • Kahn S.R.
        • Partsch H.
        • Vedantham S.
        • Prandoni P.
        • Kearon C.
        • Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
        Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization.
        J Thromb Haemost. 2009; 7: 879-883
        • Kahn S.R.
        • Lim W.
        • Dunn A.S.
        • Cushman M.
        • Dentali F.
        • Akl E.A.
        • et al.
        • American College of Chest Physicians
        Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: 195S-226S
        • Galanaud J.P.
        • Laroche J.P.
        • Righini M.
        The history and historical treatments of deep vein thrombosis.
        J Thromb Haemost. 2013; 11: 402-411
        • van Dongen C.J.
        • Prandoni P.
        • Frulla M.
        • Marchiori A.
        • Prins M.H.
        • Hutten B.A.
        Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome.
        J Thromb Haemost. 2005; 3: 939-942
        • Chitsike R.S.
        • Rodger M.A.
        • Kovacs M.J.
        • Betancourt M.T.
        • Wells P.S.
        • Anderson D.R.
        • et al.
        Risk of postthrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study.
        J Thromb Haemost. 2012; 10: 2039-2044
        • Kakkos S.K.
        • Gohel M.
        • Baekgaard N.
        • Bauersachs R.
        • Bellmunt-Montoya S.
        • Black S.A.
        • et al.
        Editor’s choice – European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis.
        Eur J Vasc Endovasc Surg. 2021; 61: 9-82
        • Kahn S.R.
        • Comerota A.J.
        • Cushman M.
        • Evans N.S.
        • Ginsberg J.S.
        • Goldenberg N.A.
        • et al.
        • American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing
        The post-thrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.
        Circulation. 2014; 130: 1636-1661
        • Watson L.
        • Broderick C.
        • Armon M.P.
        Thrombolysis for acute deep vein thrombosis.
        Cochrane Database Syst Rev. 2014; 11: CD002783
        • Alhazmi L.
        • Moustafa A.
        • Mangi M.A.
        • Alamer A.
        • Eltahawy E.
        Efficacy and safety of catheter-directed thrombolysis in preventing post-thrombotic syndrome: a meta-analysis.
        Cureus. 2019; 11: 4152
        • Lu Y.
        • Chen L.
        • Chen J.
        • Tang T.
        Catheter-directed thrombolysis versus standard anticoagulation for acute lower extremity deep vein thrombosis: a meta-analysis of clinical trials.
        Clin Appl Thromb Hemost. 2018; 24: 1134-1143
        • Xing Z.
        • Tang L.
        • Zhu Z.
        • Xu X.
        Effects of thrombolysis on outcomes of patients with deep venous thrombosis: an updated meta-analysis.
        PLoS One. 2018; 13: 0204594
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • Mulrow C.
        • Gøtzsche P.C.
        • Ioannidis J.P.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ. 2009; 339: 2700
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • Kunz R.
        • Falck-Ytter Y.
        • Alonso-Coello P.
        • et al.
        GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-926
        • Wells G.A.
        • Shea B.
        • O’Connell D.
        • Peterson J.
        • Welch V.
        • Losos M.
        • et al.
        The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital/Research Institute website.
        (Available at:)
        • Oremus M.
        • Wolfson C.
        • Perrault A.
        • Demers L.
        • Momoli F.
        • Moride Y.
        Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials.
        Dement Geriatr Cogn Disord. 2001; 12: 232-236
        • Schwarzer G.
        An R package for meta-analysis.
        R News. 2007; 7: 40-45
        • Viechtbauer W.
        Conducting meta-analyses in R with the metafor package.
        J Stat Software. 2010; 36: 1-48
        • Cheung Y.W.
        • Middeldorp S.
        • Prins M.H.
        • Pap A.F.
        • Lensing A.W.A.
        • ten Cate-Hoek A.J.
        • et al.
        • Einstein PTS Investigators Group
        Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis: a post-hoc analysis.
        Thromb Haemost. 2016; 116: 733-738
        • Jeraj L.
        • Jezovnik M.K.
        • Poredos P.
        Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome.
        Thromb Res. 2017; 157: 46-48
        • Coleman C.I.
        • Beyer-Westendorf J.
        • Bunz T.J.
        • Mahan C.E.
        • Spyropoulos A.C.
        Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism.
        Clin Appl Thromb Hemost. 2018; 24: 575-582
        • Søgaard M.
        • Nielsen B.P.
        • Skjøth F.
        • Kjældgaard J.N.
        • Coleman C.I.
        • Larsen T.B.
        Rivaroxaban vs warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism.
        Am J Med. 2018; 131: 787-794
        • Utne K.K.
        • Dahm A.
        • Wik H.S.
        • Jelsness-Jørgensen L.P.
        • Sandset P.M.
        • Ghanima W.
        Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.
        Thromb Res. 2018; 163: 6-11
        • de Athayde Soares R.
        • Matielo M.F.
        • Brochado Neto F.C.
        • Nogueira M.P.
        • Almeida R.D.
        • Sacilotto R.
        Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin.
        Surgery. 2019; 166: 1076-1083
        • Prandoni P.
        • Ageno W.
        • Ciammaichella M.
        • Mumoli N.
        • Zanatta N.
        • Imberti D.
        • et al.
        • DOAC-PTS Investigators
        The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants.
        Intern Emerg Med. 2020; 15: 447-452
        • Ferreira T.
        • Hubera S.C.
        • de Moraes Martinelli B.
        • Lemos A.J.
        • Menezes F.H.
        • Orsi A.F.
        • et al.
        Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban.
        Vasc Pharmacol. 2020; 124: 106608
        • Investigators Einstein
        • Bauersachs R.
        • Berkowitz S.D.
        • Brenner B.
        • Buller H.R.
        • Decousus H.
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N Engl J Med. 2010; 363: 2499-2510
        • Ageno W.
        • Mantovani L.G.
        • Haas S.
        • Kreutz R.
        • Monje D.
        • Schneider J.
        • et al.
        Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
        Lancet Haematol. 2016; 3: 12-21
        • Kucher N.
        • Aujesky D.
        • Beer J.H.
        • Mazzolai L.
        • Baldi T.
        • Banyai M.
        • et al.
        Rivaroxaban for the treatment of venous thromboembolism. The Swiss Venous Thromboembolism Registry (SWIVTER).
        Thromb Haemost. 2016; 116: 472-479
        • Larsen T.B.
        • Skjøth F.
        • Kjældgaard J.N.
        • Lip G.Y.H.
        • Nielsen P.B.
        • Søgaard M.
        Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
        Lancet Haematol. 2017; 13: 1-8
        • Cohen A.T.
        • Hamilton M.
        • Mitchell S.A.
        • Phatak H.
        • Liu X.
        • Bird A.
        • et al.
        Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis.
        PLoS One. 2015; 10: e0144856
        • Mantha S.
        • Ansell J.
        Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
        J Thromb Thrombolysis. 2015; 39: 155-165
        • Dawwas G.K.
        • Brown J.
        • Dietrich E.
        • Park H.
        Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
        Lancet Haematol. 2019; 6: e20-e28
        • Prandoni P.
        • Frulla M.
        • Sartor D.
        • Concolato A.
        • Girolami A.
        Vein abnormalities and the post-thrombotic syndrome.
        J Thromb Haemost. 2005; 3: 401-402
        • Dronkers C.E.A.
        • Mol G.C.
        • Maraziti G.
        • van de Ree M.A.
        • Huisman M.V.
        • Becattini C.
        • et al.
        Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis.
        Thromb Haemost. 2018; 118: 1428-1438
        • Jeraj L.
        • Kaja M.
        • Poredos P.
        Insufficient recanalization of thrombotic venous occlusion and risk for postthrombotic syndrome.
        J Vasc Interv Radiol. 2017; 28: 941-944
        • Prandoni P.
        • Ageno W.
        • Mumoli M.
        • Zanatta N.
        • Imberti D.
        • Visonà A.
        • et al.
        Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants.
        Thromb Res. 2017; 153: 97-100
        • Ramacciotti E.
        • Volpiani G.G.
        • Dávila R.
        • Resende Aguiar V.C.
        • Silveira Magella F.M.
        • Fareed J.
        Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again?.
        Int Angiol. 2018; 37: 1-3
        • Baglin T.
        Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?.
        J Thromb Haemost. 2012; 10: 1702-1703
        • Haas S.
        New oral Xa and IIa inhibitors: updates on clinical trial results.
        J Thromb Thrombolysis. 2008; 25: 52-60
        • Agnelli G.
        • Gallus A.
        • Goldhaber S.Z.
        • Haas S.
        • Huisman M.V.
        • Hull R.D.
        • et al.
        Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study.
        Circulation. 2007; 116: 180-187
        • Ellinghaus P.
        • Perzborn E.
        • Hauenschild P.
        • Gerdes C.
        • Heitmeier S.
        • Visser M.
        • et al.
        Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran.
        Thromb Res. 2016; 142: 44-51
        • Terry C.M.
        • He Y.
        • Cheung A.K.
        Rivaroxaban improves patency and decrease inflammation in a mouse model of catheter thrombosis.
        Thromb Res. 2016; 144: 106-112
        • Bouman A.C.
        • Smits J.J.M.
        • Ten Cate H.
        • Ten Cate-Hoek A.J.
        Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome.
        J Thromb Haemost. 2012; 10: 1532-1538
        • Erkens P.M.
        • ten Cate H.
        • Büller H.R.
        • Prins M.H.
        Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.
        PLoS One. 2012; 7: e42269